Embecta Aktie News

The White House recently confirmed increased tariffs on various Chinese goods. Investors and traders are on the lookout for stocks to benefit from China tariffs as the change could significantly impact many industries, including the U.S. automotive industry, electric vehicles (EVs) and others.

Embecta Corp. (NASDAQ:EMBC ) Q2 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President & Head of Investor Relations Dev Kurdikar - President, Chief Executive Officer & Director Jake Elguicze - Senior Vice President & Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Kallum Titchmarsh - Morgan Stanley Ryan Schiller - ...

PARSIPPANY, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2024.

PARSIPPANY, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 14, 2024 to stockholders of record at the close of business on May 28, 2024.

PARSIPPANY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that management will participate in the following investor events:

PARSIPPANY, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal second quarter 2024 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, May 9, 2024.

PARSIPPANY, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced its sponsorship of a symposium at the Advanced Technologies & Treatments for Diabetes (ATTD) international conference.

Embecta beat Wall Street estimates with its fiscal 2024 Q1 revenue and earnings. The company's full-year outlook, though, came in below consensus estimates.